With respect to PRL and nPRL core metrics, our results align with existing literature in people with more advanced MS assessed using various advanced imaging techniques to assess PRLs, at both 3 T and 7 T [25, 35, 36, 38, 39, 40]. The gene discussed is PRL; the disease is myeloid sarcoma.